Incretin and metabolic
Semaglutide
Lyophilized Semaglutide for laboratory research. Supplied unreconstituted.
Also searched as: sema
30 mg
€98.99
- Amount
- 5 mg, 10 mg, 15 mg, 20 mg, 30 mg
- CAS
- 910463-68-2
- Storage
- −20 °C · dry · dark
- COA
- Supplier certificate pending
About this material
Semaglutide is supplied by Rierink Compounds as a laboratory research material. Made in Europe. It sits with the peptides studied in laboratory research on incretin and metabolic signaling. The material is a lyophilized powder and is supplied unreconstituted. The companion reagent listed for it is BAC water. Store at −20 °C, dry and protected from light. For laboratory research use only. Not a medicine. Not for human or veterinary use. Rierink does not publish reconstitution volumes, dosing, or administration guidance.
Research context
Semaglutide is a GLP-1 receptor agonist peptide. Large published trials of the finished medicine, which this vial is not, have studied glycaemic control and body-weight endpoints. The material here is the lyophilized research compound only.
Published studies describe a research material and a study design. They are not a protocol for this vial, not a dose, and not a permission for human or veterinary use.
Recommended reagent
This is the laboratory reagent listed with this lyophilized material.
Also listed within
Certificates
These certificates come from our supplier and relate to the supplier's batches. They are not Rierink's own independent tests of the exact vial you receive. Every Rierink vial carries our own internal lot number, and independent testing of our own lots is underway; results will be published per lot. We welcome independent testing: any customer or lab is free to test our products, and we're happy to share results sent to us.
Supplier certificate pending
Research briefings
- Cagrilintide-Semaglutide Mixture: Open-Catalog Context and Metabolic Trial EvidenceThe open-catalog cagrilintide-semaglutide mixture supplies a research pairing of an amylin receptor agonist and GLP-1 receptor agonist for laboratory metabolic studies. Randomised trials of co-administration report enhanced weight loss (13–
- Published Reports on SemaglutidePublished reports characterize semaglutide as a long-acting GLP-1 receptor agonist with extensive randomised trial data showing 10–15% weight reduction, glycemic improvement, and cardiovascular benefits in adults with obesity or type 2 diab
- Favorable and unfavorable findings on TirzepatideClinical trials and meta-analyses of tirzepatide report substantial mean weight loss (15–21%), glycemic improvements, cardiometabolic benefits, heart failure event reduction, and superior weight loss versus semaglutide. These are accompanie
Trustpilot
A small laboratory is built one honest sentence at a time.
We're new on Trustpilot and don't have any reviews yet. Be one of the first to share your experience.
We are still the company that picks up the phone. The next researcher finds us because someone wrote down what actually happened: the lot that matched the label, the parcel that arrived late, the reply that took a day too long. That public record is how a young lab earns a name.
Write the first review